Key Takeaway: MapLight Therapeutics has reported positive results from its Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia, paving the way for a Phase 3 trial. The company is also advancing ML-007C-MA in Alzheimer's disease psychosis (ADP), with ongoing enrollment in the Phase 2 VISTA trial and topline results anticipated soon.
Market Sentiment Analysis
POSITIVE FACTORS
Positive results from the Phase 2 ZEPHYR trial of ML-007C-MA.
Advancement into a Phase 3 ZEPHYR-2 trial is supported.
Ongoing enrollment in the Phase 2 VISTA trial for ML-007C-MA.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+154%
120-day peak, hindsight
Typical move
5.2%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
ML-007C-MA
Phase 2 · Schizophrenia
Full Press Release Details
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the
Frequently Asked Questions
What were the results of the Phase 2 ZEPHYR trial?
The Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia reported positive results.
What is the next step for ML-007C-MA?
ML-007C-MA is advancing into a Phase 3 trial, known as ZEPHYR-2.
Is there ongoing research for ML-007C-MA?
Yes, enrollment is ongoing in the Phase 2 VISTA trial for ML-007C-MA.
When are topline results expected for the VISTA trial?
Topline results from the VISTA trial are expected soon.